Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
4DMedical Ltd ( (AU:4DX) ) has shared an announcement.
4DMedical Limited has been added to the S&P/ASX All Ordinaries Index as part of S&P Dow Jones Indices’ March 2026 quarterly rebalance, effective before the market opens on 23 March 2026. The reshuffle reverses earlier plans affecting African Gold Limited and American Rare Earths Limited, and brings a broad cohort of resource, technology, and healthcare names into the benchmark, enhancing visibility and potential investor interest for newly included companies such as 4DMedical.
The index inclusion marks a milestone for 4DMedical, signalling its increased market significance and potentially improving liquidity and institutional engagement with the stock. More broadly, the updated All Ordinaries composition reflects ongoing investor focus on critical minerals, energy transition, and healthcare innovation, with the changes likely to influence portfolio allocations and tracking strategies tied to Australia’s key equity benchmark.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is an Australian medical technology company that develops imaging software to analyse lung function. Its primary products focus on advanced respiratory imaging, providing clinicians with quantitative insights into pulmonary performance. The company targets healthcare providers and institutions seeking innovative diagnostic tools in respiratory medicine.
Average Trading Volume: 7,036,324
Technical Sentiment Signal: Buy
Current Market Cap: A$2.33B
See more insights into 4DX stock on TipRanks’ Stock Analysis page.